Three-Dimensional Oral Mucosal Equivalents as Models for Transmucosal Drug Permeation Studies.
3D in vitro models
3R principles
drug permeation
oral mucosal equivalents
oral transmucosal delivery
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
17 May 2023
17 May 2023
Historique:
received:
09
03
2023
revised:
12
05
2023
accepted:
12
05
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
Oral transmucosal administration, where drugs are absorbed directly through the non-keratinized, lining mucosa of the mouth, represents a solution to drug delivery with several advantages. Oral mucosal equivalents (OME) developed as 3D in vitro models are of great interest since they express the correct cell differentiation and tissue architecture, simulating the in vivo conditions better than monolayer cultures or animal tissues. The aim of this work was to develop OME to be used as a membrane for drug permeation studies. We developed both full-thickness (i.e., connective plus epithelial tissue) and split-thickness (i.e., only epithelial tissue) OME using non-tumor-derived human keratinocytes OKF6 TERT-2 obtained from the floor of the mouth. All the OME developed here presented similar transepithelial electrical resistance (TEER) values, comparable to the commercial EpiOral™. Using eletriptan hydrobromide as a model drug, we found that the full-thickness OME had similar drug flux to EpiOral™ (28.8 vs. 29.6 µg/cm
Identifiants
pubmed: 37242755
pii: pharmaceutics15051513
doi: 10.3390/pharmaceutics15051513
pmc: PMC10223481
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Crafoord Foundation
ID : 20210937
Organisme : Knowledge Foundation
ID : 20190010
Références
Biochim Biophys Acta. 2016 Nov;1861(11):1652-1661
pubmed: 27422369
Arch Oral Biol. 1995 Dec;40(12):1085-91
pubmed: 8850646
Crit Rev Oral Biol Med. 1991;2(1):13-32
pubmed: 1912142
Tissue Eng Part C Methods. 2016 Dec;22(12):1108-1117
pubmed: 27846777
Microbiology (Reading). 2009 Jun;155(Pt 6):1977-1988
pubmed: 19383683
J Invest Dermatol. 1995 Feb;104(2):224-30
pubmed: 7829878
Int J Pharm. 2014 Aug 25;471(1-2):498-506
pubmed: 24879936
Toxicol In Vitro. 2007 Aug;21(5):938-49
pubmed: 17383851
PLoS One. 2019 Oct 22;14(10):e0224228
pubmed: 31639818
Lab Invest. 2010 Oct;90(10):1425-36
pubmed: 20714325
J Lab Autom. 2015 Apr;20(2):107-26
pubmed: 25586998
Tissue Eng Part B Rev. 2020 Oct;26(5):443-460
pubmed: 32131719
J Lipid Res. 1988 Jul;29(7):949-61
pubmed: 2457643
Microb Pathog. 2011 Jun;50(6):278-85
pubmed: 21296654
Arch Oral Biol. 2005 Dec;50(12):981-7
pubmed: 15955526
J Control Release. 2012 Aug 10;161(3):746-56
pubmed: 22626941
Arch Pharm Res. 2014 Jan;37(1):96-106
pubmed: 24293063
Crit Rev Oral Biol Med. 1999;10(4):442-57
pubmed: 10634582
ALTEX. 2006;23(1):17-23
pubmed: 16477344
Mol Cell Biol. 2000 Feb;20(4):1436-47
pubmed: 10648628
J Dent Res. 2007 Feb;86(2):115-24
pubmed: 17251509
Biochim Biophys Acta. 2014 Mar;1841(3):295-313
pubmed: 24252189
Eur J Pharm Sci. 2021 Nov 1;166:105983
pubmed: 34461276
Int J Pharm. 2022 Nov 5;627:122222
pubmed: 36155795
J Invest Dermatol. 1991 Nov;97(5):771-5
pubmed: 1680930
Biochim Biophys Acta. 1993 Sep 8;1182(2):147-51
pubmed: 8357845
J Invest Dermatol. 1986 Aug;87(2):253-9
pubmed: 3090156
Expert Opin Drug Metab Toxicol. 2020 May;16(5):441-446
pubmed: 32275455
Microb Pathog. 2006 Jun;40(6):271-8
pubmed: 16626928
Int J Pharm. 2021 Jun 1;602:120609
pubmed: 33901597
In Vitro Cell Dev Biol Anim. 2003 Sep-Oct;39(8-9):388-94
pubmed: 14690452
Nat Rev Immunol. 2020 Oct;20(10):615-632
pubmed: 32887954
In Vitro Cell Dev Biol Anim. 2021 Feb;57(2):148-159
pubmed: 33447968
J Control Release. 2011 Jul 30;153(2):106-16
pubmed: 21300115
Oral Dis. 2001 Jul;7(4):252-8
pubmed: 11575877
J Natl Cancer Inst Monogr. 2001;(29):7-15
pubmed: 11694559
Organogenesis. 2015;11(3):122-36
pubmed: 26496651
Nat Protoc. 2006;1(4):2012-8
pubmed: 17487190
ALTEX. 2018;35(1):99-118
pubmed: 28800376